 |
市场调查报告书
商品编码
1773138
NPS+（美国）- 肾细胞癌NPS+ (US) - Renal Cell Carcinoma |
||||||
本报告基于100位美国肿瘤学家的洞见，分析了美国肾细胞癌治疗领域的竞争格局。运用NPS+框架，透过比较不同主要治疗方案的净推荐值，并分析医师满意度和忠诚度背后的驱动因素，提供品牌健康状况的详细视图。本报告探讨了推荐者和批评者对品牌认知的差异、与主要品牌最相关的资讯以及忠诚医生的处方价值。还透过识别转换风险并揭示每个品牌相对于竞争对手的定位，清晰地洞察当前的市场动态以及未来对品牌占有率的威胁。
关键问题
- 1.不同品牌的NPS分数如何比较？
- 2.医师对特定品牌的忠诚度如何？
- 3.哪些品牌讯息能引起医师的共鸣？
- 4.影响医师选择的主要因素有哪些？
- 5.主要品牌的市场占有率是多少？
- 6.主要品牌与竞争对手相比如何？
- 7.哪些品牌可能会因品牌满意度低而转换？
主要品牌
|
|
方法论：
First View 报告是基于透过 LiMATM 筛选出的医生进行的定量调查得出。 LiMATM 是全球最大的医生名录，拥有超过 300万名经过验证的医生。每位医生都经过严格的筛选标准，以确保收集到的见解具有相关性、可靠性，并反映顶尖医疗专业人士的真实感受和经验。调查结果以易于理解的图表形式呈现，方便快速理解和分析资料。凭藉 LiMATM 的广泛覆盖范围和精准度，FirstView Reports 提供无与伦比的资料驱动洞察，指导策略规划，并在快速发展的医疗保健领域保持领先地位。
报告有何特别之处？
FirstWord Reports 是值得信赖的行业领导者，致力于製药业，为生物製药专业人士和决策者提供详细且可操作的洞察。深厚的行业知识使能够提供相关且有价值的洞察，帮助掌握新兴趋势，有效应对复杂挑战。凭藉广泛的研究以及来自领先专家和关键意见领袖的独立、公正的见解，报告可提供所需的准确性和可靠性。独家获取其他地方无法获得的采访和资料，以及持续的市场监测，确保全面了解市场动态。报告涵盖 40 多个动态疾病领域、包括 KOL 洞察和定量医生调查在内的医生情报以及行业专家对医疗事务、数位健康、销售和营销、市场准入和其他领域问题的看法，使能够做出更明智的、资料驱动的决策，在快速变化的行业中保持竞争力。
This report examines the competitive landscape of US Renal Cell Carcinoma therapies, drawing on insights from 100 US oncologists. Using the NPS+ framework, it provides a detailed view of brand health by comparing Net Promoter Scores across key therapies and analyzing the underlying drivers of physician satisfaction and loyalty. The report explores how brand perceptions differ between Promoters and Detractors, the messages most associated with leading brands, and the prescribing value of loyal physicians. It also identifies switching risks and reveals how each brand is positioned relative to its competitors, offering a clear view of current market dynamics and future threats to brand share.
Key Questions Answered:
- 1. How do NPS scores by brand compare?
- 2. How loyal are physicians to specific brands?
- 3. What brand messages resonate with physicians?
- 4. What are the key factors driving physician choice?
- 5. What is the market share of leading brands?
- 6. How does each of the leading brands compare to its competitors?
- 7. Which brands are vulnerable to switching due to low brand satisfaction?
Key Brands:
|
|
Methodology:
FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
